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Abstract 1 
Background Trimethylamine N-oxide (TMAO) has been shown to promote the 2 
development of atherosclerosis. However, the relationship between plasma TMAO 3 
and neoatherosclerosis, an important underlying mechanism of very late stent 4 
thrombosis (VLST), is unknown. 5 
Methods This post hoc study investigated the association between TMAO and 6 
neoatherosclerosis in two independent cohorts. These included a control group of 7 
50 healthy volunteers and a study cohort of 50 patients with VLST who presented 8 
with ST-segment elevation myocardial infarction and underwent optical coherence 9 
tomography examination. Of the 50 patients with VLST, 23 had neoatherosclerosis 10 
and 27 did not have neoatherosclerosis. Patients with neoatherosclerosis were 11 
further divided into two subgroups, including 14 patients with plaque rupture and 9 12 
without plaque rupture. 13 
Results The plasma TMAO levels, detected using mass spectrometry, were 14 
significantly higher in patients with VLST than in healthy individuals (median 15 
[interquartile range]: 2.50 [1.67-3.84] vs. 1.32 [0.86-2.44] µM; P<0.001). Among the 16 
VLST patients, the plasma TMAO levels were significantly higher in patients with 17 
neoatherosclerosis than in those without neoatherosclerosis (3.69 [2.46-5.29] vs. 18 
1.96 [1.39-2.80] µM; P<0.001). In addition, in patients with neoatherosclerosis, 19 
patients with plaque rupture had significantly higher plasma TMAO concentrations 20 
than those without plaque rupture (4.51 [3.41-5.85] vs. 2.46 [2.05-3.55] µM; 21 
P=0.005). Multivariate analysis indicated that TMAO was an independent predictor 22 
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of neoatherosclerosis (odds ratio 3.41; 95% confidence interval: 1.59-7.30; 1 
P=0.002). Moreover, the area under the receiver operating characteristic curve for 2 
TMAO, differentiated by neoatherosclerosis, was 0.85. 3 
Conclusions Plasma TMAO was significantly correlated with neoatherosclerosis 4 
and plaque rupture in patients with VLST. 5 
Keywords Trimethylamine N-oxide; Optical coherence tomography; Stent 6 
thrombosis; Neoatherosclerosis; Plaque rupture 7 
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Brief summary 1 
The associations between plasma TMAO and neoatheroslcerosis and between 2 
plasma TMAO and plaque rupture, a complication of neoatherosclerosis, were 3 
investigated in patients with VLST. Plasma TMAO levels were significantly higher in 4 
patients with neoatherosclerosis than in those without neoatherosclerosis. 5 
Multivariable logistic regression analysis revealed that plasma TMAO was an 6 
independent predictor of neoatherosclerosis. In addition, in patients with 7 
neoatherosclerosis, patients with plaque rupture had significantly higher plasma 8 
TMAO concentration than those without plaque rupture. 9 
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Introduction 1 
Very late stent thrombosis (VLST), defined as thrombus formation at the stented 2 
artery segment occurring >1 year after index stent implantation, is a catastrophic and 3 
life-threatening complication of percutaneous coronary intervention (PCI).1 The 4 
incidence of VLST appears to be similar regardless of whether a bare metal stent 5 
(BMS) or drug eluting stent (DES) is used, with a cumulative rate of 1.1% for BMSs 6 
and 1.0% for DESs at 3-year follow-up.2 Although the prevalence of VLST is low, it 7 
presents a severe health burden worldwide due to its high case fatality, reported to be 8 
as high as 23.3% at 1-year follow-up,3 and the large number of patients with coronary 9 
artery disease (CAD) treated by stent implantation.4 10 
In-stent neoatherosclerosis has recently been identified as an important mechanism 11 
of VLST formation using optical coherence tomography (OCT),5, 6 an intravascular 12 
imaging modality with a high resolution, which enables in vivo visualization of the 13 
stented segment.7 Despite the prominent contribution of neoatherosclerosis in the 14 
development of VLST, its mechanisms and contributing factors are currently 15 
unknown. 16 
Trimethylamine N-oxide (TMAO), a gut-dependent metabolite generated from diets 17 
rich in phosphatidylcholine, has recently been shown to play a role in the 18 
pathogenesis and development of atherosclerosis.8, 9 In addition, elevated plasma 19 
TMAO levels have been shown to play a predictive role in determining the burden of 20 
atherosclerosis10, 11 and the risk of future cardiovascular events in patients with 21 
CAD.12, 13 However, the relationship between plasma TMAO and neoatherosclerosis 22 
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in patients with VLST remains unknown. Therefore, we aimed to investigate the 1 
relationship between plasma TMAO and neoatherosclerosis in a prospective cohort 2 
consisting of patients with ST-segment elevation myocardial infarction (STEMI) who 3 
underwent OCT examination of the culprit lesion (Optical Coherence Tomography 4 
Examination in Acute Myocardial Infarction [OCTAMI], NCT03593928). 5 
Methods 6 
Study population and design 7 
This study performed a post hoc analysis of the OCTAMI registry and comprised of 8 
two independent cohorts. The first study cohort consisted of consecutive patients 9 
(age ≥18 years) who presented with STEMI and underwent emergent procedures at 10 
Fuwai Hospital, the largest PCI centre in China. The culprit lesions of the enrolled 11 
patients were evaluated by OCT. STEMI was defined according to an established 12 
criteria.14 The exclusion criteria of the study included the following: cardiac shock, 13 
congestive heart failure, and a history of coronary artery bypass graft. Additionally, 14 
patients with left main coronary artery diseases, extremely tortuous or heavily 15 
calcified vessels, or chronic total occlusion were also excluded due to the challenge 16 
of performing OCT in these patients. Between March 2017 and April 2019, a series of 17 
470 patients with STEMI who underwent OCT examination were enrolled in the 18 
OCTAMI registry. Among these patients, 53 patients had stent thrombosis, which was 19 
defined according to the Academic Research Consortium criteria.15 The study flow 20 
chart is shown in Figure 1. The second cohort included an independent set of 50 21 
prospectively recruited, age- and sex-matched, individuals (age ≥18 years) without 22 
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any known cardiovascular diseases, detected by health screens. This cohort provided 1 
normal TMAO reference values. The study was performed in accordance with the 2 
Declaration of Helsinki and was approved by the Ethics Committee of Fuwai Hospital. 3 
All patients provided written informed consent. 4 
Classification of stents by type 5 
The underlying stents were classified as BMS (n=5), first-generation DES (n=16), 6 
second-generation DES (n=27), and unknown (n=2). The underlying stents classified 7 
as either first-generation DES or second-generation DES types are described in 8 
further detail in the supplemental materials.  9 
Acquisition of OCT imaging 10 
Patients were administered aspirin 300 mg, ticagrelor 180 mg or clopidogrel 600 mg, 11 
and heparin 100 IU/kg prior to the interventional procedure. PCI was performed via 12 
radial or femoral access. Thrombus aspiration was performed in order to reduce the 13 
thrombus burden and restore antegrade coronary flow. Small-sized balloon dilation 14 
(≤2.0 mm in diameter) at low pressures was performed in order to acquire adequate 15 
images in patients with poor quality imaging following the thrombectomy and in 16 
patients where the aspiration catheter was not able to pass the culprit lesion into the 17 
distal vessel. OCT images of the culprit lesions were acquired using the frequency 18 
domain ILUMIEN OPTIS or C7-XR OCT system and a dragonfly catheter (St. Jude 19 
Medical, Westford, MA, USA).  20 
OCT qualitative analysis 21 
All OCT images were anonymously analysed on the St Jude OCT Offline Review 22 
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Workstation (St. Jude Medical, Westford, MA, USA) by three independent 1 
experienced observers (XL, SZ, and LY), who were blinded to the other data, in a 2 
core laboratory. Inconsistent results were resolved by consensus of the investigators. 3 
Neoatherosclerosis was defined as the presence of a fibroatheroma or fibrocalcific 4 
plaque within the stented coronary segment. Fibroatheromas were characterized by a 5 
signal-poor region displaying high attenuation with diffuse borders and a lateral 6 
extension of at least one quadrant. Fibrocalcific plaques were characterised by a 7 
signal-poor region with low attenuation and clearly visible borders. Plaque rupture 8 
was identified by the presence of a disrupted fibrous cap of neoatherosclerosis, 9 
resulting in the communication of blood with the necrotic core (Figure 2). The culprit 10 
lesions, in patients without neoatherosclerosis, were categorised into uncovered 11 
struts, stent malapposition, restenosis, stent underexpansion, and edge dissection, 12 
according to an established criteria.16 Intra-observer and inter-observer variability 13 
were assessed by the evaluation of 20 randomly selected patients by the same 14 
observer and the three independent observers, respectively. The intra-observer 15 
Kappa coefficients were 0.90 for XL, 0.90 for SZ, and 0.79 for LY. The inter-observer 16 
Kappa coefficients were 0.90 for XL and SZ, 0.79 for XL and LY, and 0.89 for SZ and 17 
LY. 18 
Definitions of quantitative variables 19 
Definitions of the quantitative variables are described in the supplemental materials.  20 
Laboratory tests 21 
Blood samples were collected before heparinisation using vacutainer tubes 22 
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containing ethylenediaminetetraacetic acid. Samples were maintained at 4°C, 1 
processed within 3 hours, and then stored at -80°C until further analysis. The TMAO 2 
plasma levels were quantified using stable isotope dilution high-performance liquid 3 
chromatography with online electrospray ionization tandem mass spectrometry 4 
according to a previously described technique using an API 3200 triple quadrupole 5 
mass spectrometer (AB SCIEX, Framingham, MA, USA) with a d9-(trimethyl)–6 
labelled internal standard.17 The estimated glomerular filtration rate (mL/min/1.73 m2) 7 
was calculated using the Modification of Diet in Renal Disease study equation.18 8 
Statistical analysis 9 
Continuous data were presented as mean ± standard deviation or median 10 
[interquartile range]. Student’s t-test or nonparametric test was used for statistical 11 
comparisons, where appropriate. Categorical variables were presented as numbers 12 
(percentage); the chi-squared test or Fisher’s exact test was used to compare 13 
variables between groups. Cox proportional hazards and logistic regression analysis 14 
were performed to identify factors associated with neoatherosclerosis. The area 15 
under the receiver operating characteristic curves (AUC) was calculated to evaluate 16 
ability of plasma TMAO to predict neoatherosclerosis. A two-tailed P-value <0.05 was 17 
considered statistically significant. The statistical analyses were performed using 18 
SPSS version 22 (IBM, Armonk, NY, USA). 19 
 20 
Results 21 
Patient characteristics 22 
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Of the 470 patients with STEMI enrolled in the OCTAMI registry, 50 patients 1 
presented with VLST. In the present study, only patients with VLST were analysed 2 
and split into two strata, according to the presence or absence of neoatherosclerosis 3 
(stratum 1), and patients with neoatherosclerosis were further divided into subgroups, 4 
with or without plaque rupture as identified by OCT (stratum 2). Among them, 23 5 
patients had neoatherosclerosis, and 27 patients did not have neoatherosclerosis. 6 
Patients without neoatherosclerosis were classified as having either stent 7 
malapposition (n=11), uncovered stents (n=10), severe restenosis (n=3), stent 8 
underexpansion (n=2), or edge dissection (n=1). The 23 patients with 9 
neoatherosclerosis were further divided into two groups, including 14 patients with 10 
plaque rupture and 9 without plaque rupture (Figure 1). 11 
The patients’ baseline and clinical characteristics, according to the presence or 12 
absence of neoatherosclerosis, are shown in Table 1, and angiographic and 13 
procedural characteristics were shown in Table 2. The median stent duration from 14 
index stenting to presentation with VLST was 7.0 years. The stent duration in 5 15 
BMS-treated patients (median [interquartile range]: 14.0 [13.0-16.0] years) was 16 
significantly longer than that in the 43 DES-treated patients (7.0 [5.0-9.0] years) 17 
(P<0.001). The proportion of patients adhering to statin therapy was significantly 18 
lower in those with neoatherosclerosis than that in those without neoatherosclerosis 19 
(56.5% vs. 85.2%; P=0.031). The baseline and clinical characteristics, according to 20 
the presence or absence of plaque rupture in patients with neoatherosclerosis, are 21 
shown in Table 3. 22 
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Optical coherence tomographic morphometric analysis 1 
The OCT morphometric data, according to the presence of neoatherosclerosis, are 2 
reported in Table 4. The minimum and mean luminal area and diameter were 3 
significantly smaller in patients with neoatherosclerosis than in those without. A stent 4 
expansion index <0.8 was observed in 13.0% of patients with neoatherosclerosis and 5 
in 51.9% of patients without neoatherosclerosis (P=0.006). 6 
Comparison of plasma TMAO levels between groups 7 
We first performed a cross-sectional comparison of TMAO levels between patients 8 
with VLST and the independent set of normal healthy controls (baseline 9 
characteristics in Supplemental Table S1). The plasma TMAO levels were 10 
significantly higher in patients with VLST compared to that in normal healthy 11 
individuals (2.50 [1.67-3.84] vs. 1.32 [0.86-2.44] µM; P<0.001) (Figure 3A). 12 
In our study cohort of 50 patients with VLST, plasma TMAO levels were significantly 13 
higher in patients with neoatherosclerosis compared to that patients without 14 
neoatherosclerosis (3.69 [2.46-5.29] vs. 1.96 [1.39-2.80] µM; P<0.001) (Figure 3B). 15 
Moreover, we found significantly higher plasma TMAO levels in patients with 16 
neoatherosclerosis compared to that in normal healthy controls (P<0.001), whereas 17 
no significant difference in the plasma TMAO levels was observed between patients 18 
without neoatherosclerosis and normal healthy controls (P=0.125) (Figure 3B).  19 
We then performed a further subgroup analysis of patients with neoatherosclerosis 20 
according to the presence or absence of plaque rupture. A significantly higher plasma 21 
TMAO level was observed in patients with plaque rupture compared to that in patients 22 
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without plaque rupture (4.51 [3.41-5.85] vs. 2.46 [2.05-3.55] µM; P=0.005) (Figure 1 
3C). 2 
Predictors of in-stent neoatherosclerosis 3 
Univariate logistic regression analysis showed that TMAO levels (OR 3.43; 95% CI: 4 
1.68-6.99; P=0.001) and poor adherence to statin therapy (OR 4.42; 95% CI: 5 
1.15-16.97; P=0.030) were significantly associated with the presence of 6 
neoatherosclerosis (Supplemental Table S2). However, after adjusting for age, sex, 7 
history of hypertension and diabetes mellitus, and smoking status, plasma TMAO was 8 
found to be a unique independent predictor of neoatherosclerosis (OR 3.41; 95% CI: 9 
1.59-7.30; P=0.002) (Supplemental Table S2). 10 
Additionally, based on the significantly longer duration from index stent implantation 11 
to presentation with VLST in patients implanted with BMSs compared to that in 12 
patients with DESs, we performed a Cox regression analysis to identify whether the 13 
implantation of a DES was a predictor of neoatherosclerosis. The result indicated that 14 
DES was marginally associated with the formation of neoatherosclerosis (HR 6.73; 95% 15 
CI: 0.87-51.90; P=0.068). 16 
Diagnostic value of TMAO in neoatherosclerosis 17 
We performed a receiver operating characteristic curve analysis to evaluate the 18 
diagnostic value of TMAO in discriminating patients with neoatherosclerosis from 19 
those without neoatherosclerosis. The AUC was 0.85 (95% CI: 0.74-0.95) (Figure 4). 20 
A TMAO cut-off level of 3.23 µM was shown to be the optimal point at which the 21 
maximum summation of sensitivity and specificity, in distinguishing the presence of 22 
13 
 
neoatherosclerosis from the absence of neoatherosclerosis, is achieved. The 1 
corresponding sensitivity and specificity were 73.9% and 85.2%, respectively. 2 
 3 
Discussion 4 
The main finding of this post hoc study was the strong association between plasma 5 
TMAO level and in-stent neoatherosclerosis and the association between plasma 6 
TMAO level and plaque rupture, a complication of neoatherosclerosis, in patients with 7 
VLST. High plasma TMAO levels were found to be an independent predictor of 8 
neoatherosclerosis. Furthermore, the receiver operating characteristic curve analysis 9 
indicated that TMAO may serve as a peripheral biomarker of neoatherosclerosis. 10 
As an important underlying phenotype of VLST,5, 6 the potential mechanisms and 11 
contributing factors of neoatherosclerosis remain unknown. The gut 12 
microbiota-related metabolite TMAO has been shown to play a role in the 13 
pathogenesis and development of atherosclerotic disease.8, 10, 11 Our study 14 
contributes to these prior findings by demonstrating the significant association 15 
between plasma TMAO and neoatherosclerosis in patients with VLST. Recent 16 
mechanistic studies have suggested several potential pathways through which TMAO 17 
exerts a pro-atherosclerotic effect, including changes in macrophage phenotype, lipid 18 
metabolism, and endothelial cell activation.8, 9, 19-22 19 
An interesting finding of the present analysis was the observed similar plasma TMAO 20 
levels between patients with VLST without neoatherosclerosis and healthy controls. 21 
This indicates that the difference between patients with VLST and healthy controls 22 
14 
 
were mainly resulted from the high plasma TMAO levels in patients with 1 
neoatherosclerosis. 2 
Plaque rupture, and subsequent thrombus formation, are the main mechanisms 3 
resulting in AMI.23 Moreover, recent studies further demonstrated that plaque rupture 4 
is also the major phenotype of neoatherosclerosis leading to VLST.6 We recently 5 
reported significantly higher plasma TMAO levels in patients with plaque rupture 6 
compared to that in patients without plaque rupture who have experienced STEMI, 7 
caused by de novo lesions in native arteries as assessed by OCT.24 However, 8 
whether plasma TMAO concentration is associated with plaque rupture in patients 9 
with VLST presenting with neoatherosclerosis remains unknown. Our study extends 10 
the previous observations by demonstrating the association between elevated 11 
plasma TMAO levels and ruptured neoatherosclerotic plaques. 12 
Our study showed that plasma TMAO had an AUC of 0.85 to differentiate between 13 
patients with neoatherosclerosis and those without neoatherosclerosis, indicating that 14 
plasma TMAO may serve as a diagnostic peripheral biomarker used to predict 15 
neoatherosclerosis and provide clinical utility to improve risk stratification and the 16 
clinical management of VLST. Furthermore, as a metabolite of gut microbes from 17 
specific dietary nutrients, plasma TMAO level was demonstrated to be modifiable by 18 
dietary intervention 8, 25 or small molecular inhibitors.26, 27 Therefore, plasma TMAO 19 
has the potential of becoming a therapeutic target, used to reduce the risk of 20 
neoatherosclerosis and plaque rupture. 21 
Previous studies demonstrated that neoatherosclerosis occurred more frequently and 22 
15 
 
earlier in patients with DESs compared to that in those with BMSs.28 In our study, the 1 
Cox regression analysis showed a marginal significant association between the 2 
implantation of DESs and the formation of neoatherosclerosis in patients with VLST, 3 
which further corroborated the previous study findings. 4 
In the present analysis, patients with neoatherosclerosis had significantly smaller 5 
minimum luminal areas and diameters compared to that in patients without 6 
neoatherosclerosis, which could explain the higher rate of balloon predilation used in 7 
patients with neoatherosclerosis in this study. 8 
 9 
Limitations 10 
Several limitations exist in this study. An important limitation is the study’s lack of a 11 
control group consisting of patients with a similar duration of stent implantation 12 
without VLST. Further study is needed to identify the association between plasma 13 
TMAO and neoatherosclerosis in patients without VLST. Secondly, the plasma 14 
samples, taken from the subjects with VLST who had presented with STEMI, were 15 
not necessarily taken during a fasting state; therefore, the effects of patients’ diets on 16 
plasma TMAO levels could not be excluded. Thirdly, thrombus aspiration catheters 17 
and small-sized predilation balloons were used to acquire clear OCT images in some 18 
cases, which may affect the assessment of the morphology of the culprit lesions in 19 
patients with VLST. Lastly, this was a single-centre study with a relatively small 20 
sample size; thus, selection bias may exist. An independent study with a larger 21 
sample size is warranted to verify our study results. 22 
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Conclusions 1 
To the best of our knowledge, we are the first to investigate the association between 2 
plasma TMAO and culprit lesion morphology as assessed by OCT in patients with 3 
VLST presenting with STEMI. Our study demonstrated a significant association 4 
between plasma TMAO levels, neoatherosclerosis, and plaque rupture in patients 5 
with VLST. Further studies are warranted to explore the possibility of using plasma 6 
TMAO as a potential peripheral biomarker of neoatherosclerosis in order to improve 7 
risk stratification and the clinical management of patients with VLST. Furthermore, 8 
studies are required in order to confirm the use of plasma TMAO as an interventional 9 
target to reduce the risk of neoatherosclerosis and plaque rupture. 10 
 11 
Acknowledgements 12 
None. 13 
 14 
Funding Sources 15 
This study was supported by the Chinese Academy of Medical Sciences Innovation 16 
Fund for Medical Sciences (2016-I2M-1-009). 17 
 18 
Disclosures 19 
None.  20 
 21 
References 22 
17 
 
1. Byrne RA, Serruys PW, Baumbach A, et al. Report of a European Society of 1 
Cardiology-European Association of Percutaneous Cardiovascular Interventions task 2 
force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J 3 
2015;36:2608-20. 4 
2. Tada T, Byrne RA, Simunovic I, et al. Risk of stent thrombosis among bare-metal 5 
stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: 6 
results from a registry of 18,334 patients. JACC Cardiovasc Interv 2013;6:1267-74. 7 
3. Claessen BE, Henriques JP, Jaffer FA, Mehran R, Piek JJ, Dangas GD. Stent 8 
thrombosis: a clinical perspective. JACC Cardiovasc Interv 2014;7:1081-92. 9 
4. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent 10 
thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: 11 
data from a large two-institutional cohort study. Lancet 2007;369:667-78. 12 
5. Adriaenssens T, Joner M, Godschalk TC, et al. Optical Coherence Tomography 13 
Findings in Patients With Coronary Stent Thrombosis: A Report of the PRESTIGE 14 
Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global 15 
European Effort). Circulation 2017;136:1007-1021. 16 
6. Joner M, Koppara T, Byrne RA, et al. Neoatherosclerosis in Patients With 17 
Coronary Stent Thrombosis: Findings From Optical Coherence Tomography Imaging 18 
(A Report of the PRESTIGE Consortium). JACC Cardiovasc Interv 19 
2018;11:1340-1350. 20 
7. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on 21 
myocardial revascularization: The Task Force on Myocardial Revascularization of the 22 
18 
 
European Society of Cardiology (ESC) and the European Association for 1 
Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the 2 
European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur 3 
Heart J 2014;35:2541-619. 4 
8. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of 5 
L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 6 
2013;19:576-85. 7 
9. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine 8 
promotes cardiovascular disease. Nature 2011;472:57-63. 9 
10. Senthong V, Li XS, Hudec T, et al. Plasma Trimethylamine N-Oxide, a Gut 10 
Microbe-Generated Phosphatidylcholine Metabolite, Is Associated With 11 
Atherosclerotic Burden. J Am Coll Cardiol 2016;67:2620-8. 12 
11. Sheng Z, Tan Y, Liu C, et al. Relation of Circulating Trimethylamine N-Oxide With 13 
Coronary Atherosclerotic Burden in Patients With ST-segment Elevation Myocardial 14 
Infarction. Am J Cardiol 2019;123:894-898. 15 
12. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of 16 
phosphatidylcholine and cardiovascular risk. N Engl J Med 2013;368:1575-84. 17 
13. Li XS, Obeid S, Klingenberg R, et al. Gut microbiota-dependent trimethylamine 18 
N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular 19 
events beyond traditional risk factors. Eur Heart J 2017;38:814-824. 20 
14. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management 21 
of acute myocardial infarction in patients presenting with ST-segment elevation: The 22 
19 
 
Task Force for the management of acute myocardial infarction in patients presenting 1 
with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2 
2018;39:119-177. 3 
15. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent 4 
trials: a case for standardized definitions. Circulation 2007;115:2344-51. 5 
16. Torrado J, Buckley L, Duran A, et al. Restenosis, Stent Thrombosis, and Bleeding 6 
Complications: Navigating Between Scylla and Charybdis. J Am Coll Cardiol 7 
2018;71:1676-1695. 8 
17. Heaney LM, Jones DJ, Mbasu RJ, Ng LL, Suzuki T. High mass accuracy assay 9 
for trimethylamine N-oxide using stable-isotope dilution with liquid chromatography 10 
coupled to orthogonal acceleration time of flight mass spectrometry with multiple 11 
reaction monitoring. Anal Bioanal Chem 2016;408:797-804. 12 
18. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular 13 
filtration rate. Ann Intern Med 2009;150:604-12. 14 
19. Warrier M, Shih DM, Burrows AC, et al. The TMAO-Generating Enzyme Flavin 15 
Monooxygenase 3 Is a Central Regulator of Cholesterol Balance. Cell Rep 16 
2015;10:326-338. 17 
20. Chen ML, Zhu XH, Ran L, Lang HD, Yi L, Mi MT. Trimethylamine-N-Oxide 18 
Induces Vascular Inflammation by Activating the NLRP3 Inflammasome Through the 19 
SIRT3-SOD2-mtROS Signaling Pathway. J Am Heart Assoc 2017;6:e006347. 20 
21. Seldin MM, Meng Y, Qi H, et al. Trimethylamine N-Oxide Promotes Vascular 21 
Inflammation Through Signaling of Mitogen-Activated Protein Kinase and Nuclear 22 
20 
 
Factor-kappaB. J Am Heart Assoc 2016;5: e002767. 1 
22. Boini KM, Hussain T, Li PL, Koka S. Trimethylamine-N-Oxide Instigates NLRP3 2 
Inflammasome Activation and Endothelial Dysfunction. Cell Physiol Biochem 3 
2017;44:152-162. 4 
23. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden 5 
cardiac ischemic death. N Engl J Med 1984;310:1137-40. 6 
24. Tan Y, Sheng Z, Zhou P, et al. Plasma Trimethylamine N-Oxide as a Novel 7 
Biomarker for Plaque Rupture in Patients With ST-Segment-Elevation Myocardial 8 
Infarction. Circ Cardiovasc Interv 2019;12:e007281. 9 
25. De Filippis F, Pellegrini N, Vannini L, et al. High-level adherence to a 10 
Mediterranean diet beneficially impacts the gut microbiota and associated 11 
metabolome. Gut 2016;65:1812-1821. 12 
26. Wang Z, Roberts AB, Buffa JA, et al. Non-lethal Inhibition of Gut Microbial 13 
Trimethylamine Production for the Treatment of Atherosclerosis. Cell 14 
2015;163:1585-95. 15 
27. Roberts AB, Gu X, Buffa JA, et al. Development of a gut microbe-targeted 16 
nonlethal therapeutic to inhibit thrombosis potential. Nat Med 2018;24:1407-1417. 17 
28. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in 18 
human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 19 
2011;57:1314-22. 20 
  21 
21 
 
Table 1. Baseline characteristics of patients with and those without 1 
neoatherosclerosis  2 
 Patients with 
neoatherosclerosis 
(n=23) 
Patients without 
neoatherosclerosis 
(n=27) 
P  
value 
Age, yrs  63.7±7.2 63.2±10.2 0.816 
Male  19 (82.6) 25 (92.6) 0.395 
Body mass index, kg/m2 25.6±3.6 26.4±3.5 0.455 
Diabetes mellitus 10 (43.5) 11 (40.7) 0.845 
Insulin dependent 7 (30.4) 5 (18.5) 0.325 
Hypertension  13 (56.5) 19 (70.4) 0.309 
Smoker  15 (65.2) 21 (77.8) 0.324 
Current smoker 8 (34.8) 13 (48.1) 0.340 
Prior myocardial infarction 11 (47.8) 17 (63.0) 0.283 
Left ventricular ejection fraction, % 53.0 (45.0-59.0) 52.0 (48.0-55.0) 1.000 
Estimated glomerular filtration rate, mL/min/1.73 m2 85.6 (75.9-101.9) 83.2 (70.0-105.7) 0.553 
Triglyceride, mg/dL 121.3 (87.6-158.4) 103.6 (84.1-135.4) 0.448 
Low-density lipoprotein-cholesterol, mg/dL 84.0 (62.7-120.0) 76.2 (58.1-89.0) 0.243 
High-density lipoprotein-cholesterol, mg/dL 40.6 (33.7-44.9) 45.7 (36.0-51.5) 0.108 
High-sensitivity C-reactive protein, mg/L 5.6 (1.5-8.5) 6.5 (3.0-9.8) 0.448 
Peak troponin I, ng/mL 22.6 (9.9-66.1) 16.6 (8.1-43.7) 0.785 
D-dimer, mg/L 0.15 (0.13-0.47) 0.17 (0.13-0.37) 0.823 
22 
 
Trimethylamine N-oxide, µM 3.69 (2.46-5.29) 1.96 (1.39-2.80) <0.001 
Pre-hospital medications    
Statin  13 (56.5) 23 (85.2) 0.031 
Aspirin  15 (65.2) 18 (66.7) 0.914 
P2Y12 inhibitor 7 (30.4) 7 (25.9) 0.723 
Continuous data are presented as mean ± standard deviation or median (interquartile 1 
range), categorical variables are presented as count (%). 2 
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Table 2. Angiographic and procedural characteristics of patients with and those 1 
without neoatherosclerosis 2 
 Patients with 
neoatherosclerosis 
(n=23) 
Patients without 
neoatherosclerosis 
(n=27) 
P value 
Culprit artery   0.535 
LAD 15 (65.2) 14 (51.9)  
LCX 1 (4.3) 3 (11.1)  
RCA 7 (30.4) 10 (37.0)  
Multi-vessel disease 21 (91.3) 19 (70.4) 0.085 
Stent type at index procedure   0.285 
BMS 4 (17.4) 1 (3.7) 0.167 
First-generation DES 5 (21.7) 11 (40.7) 0.151 
Second-generation DES 13 (56.5) 14 (51.9) 0.741 
Unknown  1 (4.3) 1 (3.7) 1.000 
Stent duration, yrs 7.0 (6.0-12.0) 7.0 (3.0-10.0) 0.218 
Initial TIMI flow grade   0.769 
0 17 (73.9) 17 (63.0)  
1 1 (4.3) 2 (7.4)  
2 1 (4.3) 3 (11.1)  
3 4 (17.4) 5 (18.5)  
Thrombus aspiration 14 (60.9) 19 (70.4) 0.480 
24 
 
Balloon predilation 16 (69.6) 11 (40.7) 0.042 
Continuous data are presented as mean ± standard deviation or median (interquartile 1 
range), categorical variables are presented as count (%). BMS=bare metal stent; 2 
DES=drug-eluting stent; LAD=left anterior descending coronary artery; LCX=left 3 
circumflex coronary artery; RCA=right coronary artery; TIMI=thrombolysis in 4 
myocardial infarction  5 
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Table 3. Baseline characteristics of patients with neoatherosclerosis with and those 1 
without plaque rupture 2 
 Patients with 
plaque rupture 
(n=14) 
Patients without 
plaque rupture 
(n=9) 
P 
value 
Age, yrs  63.2±7.9 64.6±6.4 0.671 
Male  13 (92.9) 6 (66.7) 0.260 
Body mass index, kg/m2 25.0±3.5 26.5±3.7 0.323 
Diabetes mellitus 5 (35.7) 5 (55.6) 0.417 
Insulin dependent 3 (21.4) 4 (44.4) 0.363 
Hypertension  9 (64.3) 4 (44.4) 0.417 
Smoker  8 (57.1) 7 (77.8) 0.500 
Current smoker 5 (35.7) 3 (33.3) 1.000 
Prior myocardial infarction 9 (64.3) 2 (22.2) 0.089 
Left ventricular ejection fraction, % 51.5 (44.5-56.8) 57.0 (45.0-59.5) 0.394 
Estimated glomerular filtration rate, mL/min/1.73 m2 89.5 (76.2-108.2) 80.6 (75.6-96.0) 0.395 
Triglyceride, mg/dL 129.2 (98.2-170.4) 98.2 (75.2-149.6) 0.270 
Low-density lipoprotein-cholesterol, mg/dL 81.3 (61.7-120.2) 91.3 (75.7-118.2) 0.284 
High-density lipoprotein-cholesterol, mg/dL 40.2 (33.2-48.4) 41.0 (34.8-43.2) 0.753 
High-sensitivity C-reactive protein, mg/L 5.7 (2.7-10.6) 3.8 (1.2-8.4) 0.508 
Peak troponin I, ng/mL 26.7 (4.7-51.6) 18.6 (10.6-68.4) 0.950 
D-dimer, mg/L 0.14 (0.13-0.42) 0.25 (0.13-0.52) 0.311 
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Trimethylamine N-oxide, µM 4.51 (3.41-5.85) 2.46 (2.05-3.55) 0.005 
Pre-hospital medications    
Statin  6 (42.9) 7 (77.8) 0.197 
Aspirin  8 (57.1) 7 (77.8) 0.400 
P2Y12 inhibitor 5 (35.7) 2 (22.2) 0.657 
Continuous data are presented as mean ± standard deviation or median (interquartile 1 
range), categorical variables are presented as count (%).   2 
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Table 4. Optical coherence tomographic morphometric analysis in patients with and 1 
those without neoatherosclerosis 2 
 Patients with 
neoatherosclerosis 
(n=23) 
Patients without 
neoatherosclerosis 
(n=27) 
P value 
Minimum stent area, mm2 6.32±2.01 6.22±1.61 0.846 
Mean stent area, mm2 7.33±2.07 7.72±1.87 0.485 
Minimum stent diameter, mm 2.80±0.44 2.77±0.36 0.811 
Mean stent diameter, mm 3.02±0.41 3.09±0.38 0.574 
Minimum luminal area, mm2 1.63±0.57 3.67±1.63 <0.001 
Mean luminal area, mm2 3.52±0.86 5.49±1.65 <0.001 
Minimum luminal diameter, mm 1.41±0.24 2.10±0.47 <0.001 
Mean luminal diameter, mm 2.01±0.25 2.55±0.40 <0.001 
Proximal luminal area, mm2 7.99±2.41 9.38±2.56 0.055 
Proximal luminal diameter, mm 3.15±0.47 3.42±0.49 0.053 
Distal luminal area, mm2 5.73±2.04 6.21±2.15 0.417 
Distal luminal diameter, mm 2.65±0.46 2.76±0.50 0.398 
Reference area, mm2 6.86±2.09 7.80±2.18 0.127 
Reference diameter, mm 2.90±0.44 3.10±0.46 0.136 
Expansion index 0.93±0.13 0.81±0.12 0.003 
Stent expansion <80% 3 (13.0) 14 (51.9) 0.006 
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Continuous data are presented as mean ± standard deviation, categorical variables 1 
are presented as count (%).  2 
29 
 
Figure legends 1 
Figure 1. Study flowchart  2 
A study flow of patients who are stratified according to the presence or absence of 3 
neoatherosclerosis (stratum 1) and plaque rupture (stratum 2). OCTAMI=Optical 4 
Coherence Tomography Examination in Acute Myocardial Infarction, 5 
STEMI=ST-segment elevation myocardial infarction. 6 
Figure 2. Representative images of OCT findings in patients presenting with very late 7 
stent thrombosis  8 
(A) Neoatherosclerosis with a lipid-rich plaque (white arrows) and plaque rupture, 9 
accompanied by a cavity (asterisk) and thrombus formation (thr). (B) 10 
Neoatherosclerosis with a fibrocalcific plaque (yellow arrows), without plaque rupture, 11 
accompanied by thrombus formation (thr). (C) Malapposed struts with thrombus 12 
formation (thr). (D) Uncovered struts with thrombus formation (thr). 13 
Figure 3. Comparison of plasma trimethylamine N-oxide (TMAO) levels between the 14 
different groups  15 
(A) Plasma TMAO level in healthy controls compared to that in patients with very late 16 
stent thrombosis. (B) Plasma TMAO level in patients with neoatherosclerosis 17 
compared to that in patients without neoatherosclerosis and that in healthy controls. 18 
(C) Plasma TMAO level in patients with plaque rupture compared to that in patients 19 
without plaque rupture. NE=neoatherosclerosis. 20 
Figure 4. Receiver operating characteristic curve of trimethylamine N-oxide for 21 
predicting neoatherosclerosis in patients with very late stent thrombosis. AUC, area 22 
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under the receiver operating characteristic curve. 1 
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